Sun Pharma Industries has revealed a $100 million investment to commercialize new, innovative specialty products in the ongoing fiscal year. The pharmaceutical giant, based in Mumbai, is trying to expand its portfolio of patented products in oncology and dermatology treatments.
1. Major Investments and Product Launches
Sun Pharma will invest heavily in the launch of two specialty medicines:
-
Unloxcyt – A metastatic cutaneous squamous cell carcinoma treatment.
-
Leqselvi – A treatment for severe alopecia areata.
The company is also looking for a partner to develop MM-II in the future, a pain treatment for osteoarthritis.
2. Strategic Expansion and Market Growth
-
Sun Pharma's worldwide specialty sales increased 17.1% year on year to $1.216 billion in FY25, with Q4 sales at $295 million.
-
The company anticipates mid-to-high single-digit consolidated topline growth in FY26.
-
Sun Pharma has agreed to buy Checkpoint Therapeutics, a company focused on immunotherapy and targeted oncology.
3. Future Projections and R&D Expenditures
-
The company will start a trial of GL0034 with type 2 diabetes as its initial indication.
-
Sun Pharma's R&D expenditure for FY26 will be 6-8% of total sales, reaffirming its focus on innovation and drug development.
Sources: MSN, The Hindu Business Line, The Economic Times